trending Market Intelligence /marketintelligence/en/news-insights/trending/tci83ppmfn9azagpmjbbxa2 content esgSubNav
In This List

Pfizer's Hospira recalls 3 lots of pain medication injection

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Pfizer's Hospira recalls 3 lots of pain medication injection

Pfizer Inc.'s unit Hospira is recalling three lots of an opioid pain medication injection due to potential lack of sterility resulting from damaged units.

The company is voluntarily recalling the lots of hydromorphone hydrochloride due to the possibility that units from these lots may be empty or cracked at the bottom of the glass vial.

Exposure to cracked units may be related to adverse events such as sharp injury to healthcare professionals. Intravenous infusion of a nonsterile solution can lead to bloodstream infections, which may potentially lead to bacteremia or sepsis.

Hydromorphone hydrochloride is an opioid agonist approved to manage pain that is severe enough to require an opioid analgesic and for which alternative treatments are not enough.